Cardiology Month in Review: April 2024
The April 2024 cardiology month in review spotlights FDA news and top updates from the American College of Cardiology 2024 Scientific Session.
The April 2024 cardiology month in review spotlights FDA news and top updates from the American College of Cardiology 2024 Scientific Session.
Fadi Fakhouri, MD, PhD, disuccess the 1-year results of the NOBLE trial examining use of pegcetacoplan in patients with post-transplant C3G or IC-MPGN.
Zach Klaassen and Kelvin Moses discuss the continuum of care for metastatic hormone-sensitive prostate cancer, focusing on triplet therapy. Dr. Moses highlights the ideal patient…
Circulating antinephrin autoantibodies identified as reliable biomarkers for MCD and primary FSGS, enhancing diagnostic precision and monitoring of nephrotic syndromes.
In the APPEAR-C3G trial, iptacopa reduced proteinuria by 35.1% in patients with C3 glomerulopathy, with Novartis planning regulatory submissions for before the end of 2024.
InPACT trial, penile cancer, Squamous Cell Cancer of the Penis, Radiotherapy in the Management of Squamous Cell Cancer of the Penis, InPact trial, ECOG-ACRIN, GOG…
Hear from Katharina Mayer, MD, and Georg Böhmig, MD, on the results of the phase 2 trial of felzartamab in patients with antibody-mediated rejection following…
By prioritizing continuous patient engagement and strategic communication across the entire care journey, healthcare organizations can drive real progress toward value-based care.
An early-stage clinical trial of a radiopharmaceutical drug developed by J&J showed some signs of efficacy in prostate cancer patients, but four participants in the…
Andrea Miyahira hosts Ping Mu to discuss his group’s research on prostate cancer resistance to anti-androgens. Dr. Mu’s study, published in Oncogene, focuses on the…
A phase 2b dose-finding study suggests use of clazakizumab was associated with a reduction in hs-CRP among patients undergoing maintenance dialysis.